Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.

Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active and passive immunization. Here we review current immunologic strategies for HIV-1 prevention, with a focus on current and next-generation vaccines and bNAbs.

• Publication year

  2020

• Venue

  Annual Review of Immunology

• Publication date

  2020-04-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1146/annurev-immunol-080219-023629PMID 32340576PMCID PMC7375352
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens

  2019cited by this paper
• The Antibodiome—Mapping the Humoral Immune Response to HIV

  2019cited by this paper
• Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies

  2019cited by this paper
• A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge.

  2019cited by this paper
• Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)

  2019cited by this paper
• Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET.

  2019cited by this paper
• Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

  2019cited by this paper
• Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa

  2019cited by this paper
• Immunization expands HIV-1 V3-glycan specific B-cells in mice and macaques

  2019cited by this paper
• Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence

  2019cited by this paper
• The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template

  2019cited by this paper
• Structural topology defines protective CD8+ T cell epitopes in the HIV proteome

  2019cited by this paper
• Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers

  2019cited by this paper
• HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design

  2019influential reference
• Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption

  2018cited by this paper
• Glycan Masking Focuses Immune Responses to the HIV‐1 CD4‐Binding Site and Enhances Elicitation of VRC01‐Class Precursor Antibodies

  2018cited by this paper
• eCD4-Ig Variants That More Potently Neutralize HIV-1

  2018cited by this paper
• Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review

  2018cited by this paper
• Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1

  2018cited by this paper
• Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections

  2018cited by this paper
• Recent progress in broadly neutralizing antibodies to HIV

  2018cited by this paper
• Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study.

  2018cited by this paper
• Strategies for a multi-stage neutralizing antibody-based HIV vaccine.

  2018cited by this paper
• Reviewers ' comments : Reviewer # 1

  2018cited by this paper
• Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection

  2018cited by this paper
• Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995–2015

  2018cited by this paper
• Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

  2018cited by this paper
• Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

  2018influential reference
• Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.

  2018cited by this paper
• Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development

  2018cited by this paper
• Correlates of Protection Against SIVmac251 Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors

  2018cited by this paper
• Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

  2018cited by this paper
• Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

  2018influential reference
• Combination therapy with anti-HIV-1 antibodies maintains viral suppression

  2018cited by this paper
• Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117

  2018cited by this paper
• Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth

  2018cited by this paper
• Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope

  2018cited by this paper
• Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

  2018cited by this paper
• Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide

  2017cited by this paper
• Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development

  2017cited by this paper
• The HIV‐1 envelope glycoprotein structure: nailing down a moving target

  2017cited by this paper
• Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model

  2017cited by this paper
• Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

  2017cited by this paper
• A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure

  2017cited by this paper
• Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells

  2017cited by this paper
• Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches

  2017cited by this paper
• Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

  2017cited by this paper
• Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses.

  2017cited by this paper
• The vaccine wars.

  2017cited by this paper
• Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches

  2017cited by this paper
• Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

  2017cited by this paper
• Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows

  2017cited by this paper
• Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

  2017cited by this paper
• Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

  2017cited by this paper
• Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

  2017cited by this paper
• Polyvalent vaccine approaches to combat HIV‐1 diversity

  2017cited by this paper
• Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies

  2017cited by this paper
• Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

  2017cited by this paper
• Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

  2017cited by this paper
• Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.

  2016cited by this paper
• Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort

  2016cited by this paper
• Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies.

  2016cited by this paper
• HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies

  2016cited by this paper
• Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.

  2016cited by this paper
• Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

  2016cited by this paper
• D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers

  2016cited by this paper
• Antiretroviral Therapy for the Prevention of HIV-1 Transmission.

  2016cited by this paper
• Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

  2016cited by this paper
• A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

  2016cited by this paper
• Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G.

  2016cited by this paper
• Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

  2016cited by this paper
• Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site

  2016cited by this paper
• HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

  2016cited by this paper
• Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice

  2016cited by this paper
• Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.

  2016cited by this paper
• Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials.

  2016cited by this paper
• Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E

  2016cited by this paper
• Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C

  2016cited by this paper
• Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

  2016cited by this paper
• Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

  2016cited by this paper
• Determinants of HIV-1 broadly neutralizing antibody induction

  2016cited by this paper
• Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

  2016cited by this paper
• Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus

  2016cited by this paper
• HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

  2016cited by this paper
• Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition.

  2016cited by this paper
• A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.

  2016cited by this paper
• Announcement: Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016.

  2016cited by this paper
• Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

  2016cited by this paper
• Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection.

  2016cited by this paper
• Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody.

  2016cited by this paper
• Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies

  2016cited by this paper
• HIV-1 neutralizing antibodies induced by native-like envelope trimers

  2015cited by this paper
• A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques

  2015cited by this paper
• Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies

  2015cited by this paper
• HIV pre-exposure prophylaxis in transgender women: A subgroup analysis of the iPrEx trial

  2015cited by this paper
• On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

  2015cited by this paper
• Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.

  2015cited by this paper
• Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.

  2015cited by this paper
• Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies

  2015cited by this paper
• Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen

  2015cited by this paper

• Simultaneous priming of HIV broadly neutralizing antibody precursors to multiple epitopes by germline-targeting mRNA-LNP immunogens in mouse models

  2025cites this paper
• Health Technology Assessment of mRNA Vaccines: Clinical, Economic, and Public Health Implications

  2025cites this paper
• Development of a Virus Particle-Based Antibody-Dependent Cellular Phagocytosis (ADCP) Assay for HIV

  2025cites this paper
• Harnessing the Potential of mRNA Vaccines Against Infectious Diseases

  2025cites this paper
• Macrophages direct location-dependent recall of B cell memory to vaccination.

  2025cites this paper
• Autovaccination revisited: potential to boost antiviral immunity and facilitate HIV-1 cure/remission in children

  2025cites this paper
• Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge

  2025cites this paper
• HIV diagnosis during acute infection: implications of long-acting preexposure prophylaxis and other evolving challenges

  2025cites this paper
• Incompletely closed HIV-1CH040 envelope glycoproteins resist broadly neutralizing antibodies while mediating efficient HIV-1 entry

  2025cites this paper
• Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial.

  2025cites this paper
• Vaccination against pathogens targeting cell-derived cryptic antigens.

  2025cites this paper
• Deep Mining of the Human Antibody Repertoire Identifies Frequent and Genetically Diverse CDRH3 Topologies Targetable by Vaccination

  2025cites this paper
• Consistent Induction of Broadly Neutralizing HIV Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design

  2025cites this paper
• Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1

  2024cites this paper
• A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication

  2024cites this paper
• HIResist: a database of HIV-1 resistance to broadly neutralizing antibodies

  2024cites this paper
• [A comprehensive analysis on economic evaluation of HIV vaccination strategies].

  2024cites this paper
• Biomaterial engineering strategies for B cell immunity modulations

  2024cites this paper
• Minimal framework for optimizing vaccination protocols targeting highly mutable pathogens.

  2024cites this paper
• A Targeted Vaccination Strategy: Integrating Vaccines into Biosafety, Biosecurity, and One Health Initiatives

  2024cites this paper
• HIV vaccination: Navigating the path to a transformative breakthrough—A review of current evidence

  2024cites this paper
• HIV Vaccine Development at a Crossroads: New B and T Cell Approaches

  2024cites this paper
• Research on Maternal Vaccination for HIV Prevention.

  2024cites this paper
• Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial

  2024cites this paper
• Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1

  2024cites this paper
• The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention

  2024cites this paper
• The Role of MicroRNAs in HIV Infection

  2024cites this paper
• Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives

  2024cites this paper
• A Minimal Framework for Optimizing Vaccination Protocols Targeting Highly Mutable Pathogens.

  2024cites this paper
• Glycan-Imprinted Nanoparticle as Artificial Neutralizing Antibody for Efficient HIV-1 Recognition and Inhibition.

  2024cites this paper
• High Genetic Diversity of HIV-1 and Active Transmission Clusters among Male-to-Male Sexual Contacts (MMSCs) in Zhuhai, China

  2023cites this paper
• Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?

  2023cites this paper
• Dysregulation of memory B cells and circulating T follicular helper cells is a predictor of poor immune recovery in HIV‐infected patients on antiretroviral therapy

  2023cites this paper
• Adeno-associated virus-vectored delivery of HIV biologics: the promise of a “single-shot” functional cure for HIV infection

  2023cites this paper
• Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage

  2023cites this paper
• An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates

  2023cites this paper
• Polyfunctionality of broadly neutralizing HIV-1 antibodies

  2023cites this paper
• Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage

  2023influential citation
• Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations

  2023cites this paper
• Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility

  2023cites this paper
• Engaging an HIV vaccine target through the acquisition of low B cell affinity

  2023cites this paper
• Anticipating HIV viral escape – resistance to active and passive immunization

  2023cites this paper
• HIV infection

  2023cites this paper
• Broadly neutralizing antibodies targeting HIV: Progress and challenges.

  2023cites this paper
• Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility

  2023cites this paper
• Strategies for HIV-1 suppression through key genes and cell therapy

  2023influential citation
• Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.

  2023cites this paper
• Antigen-specific memory NK cell responses against HIV and influenza use the NKG2/HLA-E axis

  2023cites this paper
• High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials

  2023cites this paper
• Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

  2022cites this paper
• Rational Engineering of a Sub-Picomolar HIV-1 Blocker

  2022cites this paper
• Multivalent display of engineered HIV-1 envelope trimers on silica nanoparticles for targeting and in vitro activation of germline VRC01 B cells.

  2022cites this paper
• Molecular Basis for the Recognition of HIV Nef138-8 Epitope by a Pair of Human Public T Cell Receptors

  2022cites this paper
• Structural basis for breadth development in a HIV-1 neutralizing antibody

  2022cites this paper
• Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

  2022cites this paper
• Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection

  2022cites this paper
• Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies

  2022cites this paper
• Insertions and Deletions (Indels): A Missing Piece of the Protein Engineering Jigsaw.

  2022cites this paper
• Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

  2022cites this paper
• Model systems of human immunodef iciency virus (HIV-1) for in vitro eff icacy assessment of candidate vaccines and drugs against HIV-1

  2022cites this paper
• Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller

  2022cites this paper
• A surface protein−imprinted biosensor based on boronate affinity for the detection of anti−human immunoglobulin G

  2022cites this paper
• Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals

  2022cites this paper
• Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?

  2022cites this paper
• Broadly neutralizing antibodies for HIV-1 prevention and therapy.

  2021cites this paper
• Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B′ Infected Plasma Donor with Broadly Neutralizing Activity

  2021cites this paper
• Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV

  2021cites this paper
• Broadly neutralizing monoclonal antibodies for HIV prevention

  2021cites this paper
• Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy

  2021cites this paper
• Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement

  2021cites this paper
• Broadly neutralizing HIV-1 antibody reactivity in HIV tests: implications for diagnostics

  2021cites this paper
• Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy

  2021cites this paper
• Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge

  2021cites this paper
• IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ T cells

  2021cites this paper
• Deep sequencing of the HIV-1 polymerase gene for characterisation of cytotoxic T-lymphocyte epitopes during early and chronic disease stages

  2021cites this paper
• To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1

  2021cites this paper
• Phage display as a tool for identifying HIV-1 broadly neutralizing antibodies

  2021cites this paper
• Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention

  2021cites this paper
• Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1.

  2021cites this paper
• Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge.

  2021cites this paper
• Identification of a CD4-binding site-directed antibody with ADCC activity from a chronic HIV-1B'-infected Chinese donor.

  2021cites this paper
• HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens

  2021cites this paper
• Antibody response against selected epitopes in the HIV-1 envelope gp41 ectodomain contributes to reduce viral burden in HIV-1 infected patients

  2021cites this paper
• Extremely Thermostabilizing Core Mutations in Coiled-Coil Mimetic Proteins of HIV-1 gp41 Produce Diverse Effects on Target Binding but Do Not Affect Their Inhibitory Activity

  2021cites this paper
• HIV Vaccine Development: 35 Years of Experimenting in the Funding of Biomedical Research

  2020cites this paper
• Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses

  2020cites this paper
• IgA Summons IgG to Take a Hit at HIV-1.

  2020influential citation
• Optimal evolutionary decision-making to store immune memory

  2020cites this paper
• Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies.

  2020cites this paper
• T Cell Epitope Predictions.

  2020cites this paper
• Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses

  2020cites this paper
• Immunological approaches to HIV cure.

  2020cites this paper
• Conjugation of Native-Like HIV-1 Envelope Trimers onto Liposomes Using EDC/Sulfo-NHS Chemistry: Requirements and Limitations

  2020cites this paper
• Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth

  2020cites this paper
• Neutralizing Antibodies Targeting HIV-1 gp41

  2020cites this paper
• Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era

  2020cites this paper
• Lactobacilli Expressing Broadly Neutralizing Nanobodies against HIV-1 as Potential Vectors for HIV-1 Prophylaxis?

  2020cites this paper
• Editing of the TRIM5 Gene Decreases the Permissiveness of Human T Lymphocytic Cells to HIV-1

  2020cites this paper
• One-shot Evaluation of Protein Mutability and Epistasis Score Using Structure-Based Model ESM3

  year unknowncites this paper